Clinical trials: Painful Peripheral Diabetic Neuropathy
Painful Peripheral Diabetic Neuropathy
A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy
Evaluate the effectiveness of the Provant Therapy System compared to sham on pain sensitivity and nervous system response to various qualities of experimentally induced pain in the upper and lower extremities of subjects with…
- Trial name
- NCT02809911
- Testing
- Provant
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Regenesis Biomedical, Inc.
Diabetic Neuropathy, Painful
Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy
The purpose of this study is to assess the safety and the preliminary efficacy of treatment by the VascuActive device on peripheral diabetic neuropathy, and to correlate this effect with physiologic changes.
- Trial name
- NCT01214590
- Testing
- VascuActive device
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- VascuActive LTD
Peripheral Neuropathy, Neuropathic Pain
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of…
- Trial name
- NCT00603265
- Testing
- ADL5859, Duloxetine
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Diabetic Neuropathy, Painful, Diabetic Neuralgia
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200 mg of RWJ-333369 given twice daily by mouth compared with placebo in the treatment of Diabetic Peripheral Neuropathy (DPN).
- Conditions
- Diabetic Neuropathy, Painful, Diabetic Neuralgia, Diabetic Polyneuropathy, Diabetic Mononeuropathy
- Trial name
- NCT00501202
- Testing
- RWJ-333369 (carisbamate)
- Volunteers
- 132 people
- Sponsor
- SK Life Science, Inc.
Diabetic Foot Ulcer (DFU), Diabetic Symmetrical Polyneuropathy
Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing
Diabetic symmetrical polyneuropathy (DSPN) is a common complication of diabetes that affects the nerves, especially in the legs and feet. It can cause pain, numbness, tingling, weakness, and loss of sensation.
- Trial name
- NCT07877948
- Testing
- Alpha-Lipoic Acid, Vitamin B1, Vitamin B6, Vitamin B12, Vitamin E, Vitamin B1, Vitamin B6, Vitamin B12
- Where
- Malaysia
- Volunteers
- 100 people
- Sponsor
- BREGO Life Sciences
Painful Diabetic Peripheral Neuropathy (PDPN)
Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo.
- Trial name
- NCT02372578
- Testing
- ASP3662, pregabalin
- Where
- 37 sites in United States
- Volunteers
- 115 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Diabetic Neuropathy, Painful
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)
- Trial name
- NCT02215252
- Testing
- PF-05089771 150 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
- Where
- 32 sites in United States
- Volunteers
- 141 people
- Sponsor
- Pfizer
Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
- Trial name
- NCT06628908
- Testing
- Suzetrigine, Pregabalin
- Where
- 76 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetic Neuropathy, Painful
A Study in Painful Diabetic Neuropathy
This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not…
- Trial name
- COMBO-DN (NCT01089556)
- Testing
- Duloxetine, Pregabalin
- Where
- 54 sites in Australia, Canada and 14 more
- Volunteers
- 811 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy, Painful
Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy
The purposes of this study are to: 1) find out if pregabalin relieves pain in subjects with painful diabetic peripheral neuropathy; 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day); and 3) find out if…
- Trial name
- NCT00159679
- Testing
- Pregabalin
- Where
- 30 sites in United States
- Volunteers
- 167 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Peripheral Neuropathy
Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy
To investigate the effect of repeat oral dosing of CNV2197944 75 mg tid on the pain experienced in diabetic peripheral neuropathy (DPN) as measured by changes in PI-NRS after three weeks of treatment compared to the baseline…
- Trial name
- NCT01893125
- Testing
- CNV2197944
- Where
- Hungary
- Volunteers
- 126 people
- Sponsor
- Convergence Pharmaceuticals
Diabetic Neuropathy, Painful
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy and safety of intramuscular administration of Engensis on pain in participants with painful diabetic peripheral neuropathy in the feet and lower legs, as compared to Placebo…
- Trial name
- REGAiN-1A (NCT04469270)
- Testing
- Engensis
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Helixmith Co., Ltd.
Diabetic Neuropathy, Chemotherapy Induced Neuropathy
A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy
A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.
- Conditions
- Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
- Trial name
- Neuron012703 (NCT01537705)
- Testing
- Neuron012703 (Medical Food)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Targeted Medical Pharma
Diabetic Neuropathic Pain
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain
People with diabetes can, over time develop nerve damage throughout the body with symptoms such as pain, tingling, or numbness (loss of feeling) in the hands, arms, feet and legs.
- Trial name
- NCT01345045
- Testing
- ABT-639, pregabalin
- Where
- 35 sites in United States, Czechia and 3 more
- Volunteers
- 193 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Painful Diabetic Neuropathy
Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy
The purpose of this study is to determine whether ARC-4558 is effective in managing pain associated with painful diabetic neuropathy.
- Trial name
- NCT00695565
- Testing
- Clonidine Topical Gel (ARC-4558)
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- Arcion Therapeutics Inc
Pain, Diabetic Neuropathy
A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving pain due to Diabetic Neuropathy.
- Trial name
- NCT00710424
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 297 people
- Sponsor
- Jazz Pharmaceuticals
Painful Diabetic Neuropathy
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Diabetic Neuropathic Pain (DNP) over a 15 week treatment phase.
- Trial name
- NCT01129960
- Testing
- Eslicarbazepine acetate (BIA 2-093)
- Where
- Portugal
- Volunteers
- 332 people
- Sponsor
- Bial - Portela C S.A.
Diabetic Neuropathy
A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of Tapentadol (CG5503) extended release (ER) (base) compared to placebo in patients with moderate to severe pain from diabetic…
- Trial name
- NCT00455520
- Testing
- CG5503
- Volunteers
- 395 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Neuropathy, Diabetic, Neuropathy;Peripheral
Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic…
- Conditions
- Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
- Trial name
- NCT05291975
- Testing
- Erchonia® EVRL™
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Erchonia Corporation
Healthy
Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg
The purpose of this clinical trial is to (1) evaluate the bioequivalence(BE) of GLA5PR GLARS-NF3 tablet 150mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 150mg administered regular diet and (2) determine the…
- Trial name
- NCT02955472
- Testing
- GLA5PR GLARS-NF3 tablet 150mg, GLA5PR GLARS-NF1 tablet 150mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation